<DOC>
	<DOCNO>NCT01706055</DOCNO>
	<brief_summary>This prospective , multicentre , observational study . Patients initiate treatment IFNβ-1b ( Betaferon ) follow 6 month . Baseline visit ( visit 0 ) i.e . treatment initiation plus four follow-up visit ( visit 1-4 ) . For patient demographic , medical history data , safety parameter , presence flu-like symptom measure prevent treat symptom collect .</brief_summary>
	<brief_title>Assessment Strategies Management Flu-like Symptoms MS Patients Commencing Treatment With Betaferon ( INFLUENCE )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Diagnosis relapsingremitting multiple sclerosis ( RRMS ) accord McDonald ( 2005 ) criterion Age &gt; /= 18 year old Treatment MS patient attend physician decide initiate therapy interferon beta1b ; Betaferon Minimum 6 month washout period previous IFNβ Written Informed Consent sign Patients previously treat disease modify drug ( DMDs ) , exception IFNβ therapy end least 6 month earlier Patients receive treatment IFN beta Betaferon ( Bayer )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Multiple Sclerosis ( MS )</keyword>
	<keyword>Interferon</keyword>
</DOC>